Clinical Trial Update: Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study [Phase 2]

View source ↗

Summary

A Phase 2, double-blind trial evaluated the efficacy of 500 µg roflumilast once daily versus placebo for 12 weeks in adults with Type 2 diabetes mellitus; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Roflumilast (Daliresp) (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus Type 2 | Phase 2 | Status: COMPLETED